Oncology Services Clinical to Genomic SmartGenomics ™ Prostate Proﬁle Advanced Standard of Care PathGroup SmartGenomics: Prostate is designed for use at diagnosis of primary or metastatic prostate carcinoma to uncover therapeutic options and aid in treatment planning to improve patient outcomes. 4 Clinically actionable genomic information for 44 gene mutations, cytogenetic abnormalities (FISH), and whole genome copy number changes (CMA) from a single biopsy 4 Fully integrated testing on every case for a complete patient picture Tailored Genomic Prostate Profile pathgroup.com | 855-854-6473 Next Generation Sequencing (NGS) AKT1 Therapeutic implications via PI3K/AKT/mTOR inhibition APC Therapeutic target, independent predictor of a poor prognosis in prostate cancer ARAF Potential therapeutic targets ATM Confers sensitivity to platinums and PARP inhibitors BRAF Potential therapeutic target BRCA1/2 Confers sensitivity to platinums and PARP inhibitors CDKN2A Plays a critical role in prostate cancer progression, prognostic marker CTNNB1 Potential therapeutic target EGFR Prognostic value in prostate cancer, potential therapeutic target ERBB2/4 Related to metastatic potential of prostate cancer FBXW7 Tumor suppressor linked to prognosis FGFR1/2/3/4 Potential driver mutation and therapeutic target IDH1/2 Deregulates cellular metabolism, potential therapeutic target JAK1/2/3 Potential therapeutic targets KDR Recently discovered gene of importance in prostate cancer KIT Promotes migration and invasion of prostate cancer cells KRAS Potential therapeutic target MET Therapeutic target NF1/2 Tumor suppressor function, potential prognostic value NOTCH1 Deregulation is a feature of tumorigenesis NRAS Potential therapeutic target NTRK1/2/3 Potential gene fusion partner, therapeutic target PDGFRA Potential therapeutic target PIK3CA Potential response to TORC1 inhibitor rapamycin and its analogues: everolimus, temsirolimus, and ridaforolimus PTEN Potential response to mTOR inhibitor everolimus, PI3K / AKT inhibitors under study SMAD4 Suspected gatekeeper gene SMO Implicated in the development of PCa and progression to more advanced and castration-resistant disease SRC Potential therapeutic target STK1 Tumor suppressor gene TP53 Patients with TP53 mutations may have better outcomes with bevacizumab, therapeutic target TSC1/2 Suspected gatekeeper gene VHL Potential regulator of PDL1 expression (proﬁle components listing continued on back)

Tailored Genomic Prostate Profile - PathGroup...Prostate Profile Advanced Standard of Care PathGroup SmartGenomics: Prostate is designed for use at diagnosis of primary or metastatic

Download PDF Report

Upload
others
View
4
Download
0

Embed Size (px)

Citation preview

Oncology Services

Clinical to Genomic

SmartGenomics ™

Prostate Profile

Advanced Standard of CarePathGroup SmartGenomics: Prostate is designed for use at diagnosis of primary or metastatic prostate carcinoma to uncover therapeutic options and aid in treatment planning to improve patient outcomes.

4 Clinically actionable genomic information for 44 gene mutations, cytogenetic abnormalities (FISH), and whole genome copy number changes (CMA) from a single biopsy

4 Fully integrated testing on every case for a complete patient picture

Tailored Genomic Prostate Profile

pathgroup.com | 855-854-6473

Next Generation Sequencing (NGS)AKT1 Therapeutic implications via PI3K/AKT/mTOR inhibitionAPC Therapeutic target, independent predictor of a poor prognosis in prostate cancerARAF Potential therapeutic targetsATM Confers sensitivity to platinums and PARP inhibitorsBRAF Potential therapeutic targetBRCA1/2 Confers sensitivity to platinums and PARP inhibitorsCDKN2A Plays a critical role in prostate cancer progression, prognostic markerCTNNB1 Potential therapeutic targetEGFR Prognostic value in prostate cancer, potential therapeutic targetERBB2/4 Related to metastatic potential of prostate cancerFBXW7 Tumor suppressor linked to prognosisFGFR1/2/3/4 Potential driver mutation and therapeutic targetIDH1/2 Deregulates cellular metabolism, potential therapeutic targetJAK1/2/3 Potential therapeutic targetsKDR Recently discovered gene of importance in prostate cancerKIT Promotes migration and invasion of prostate cancer cellsKRAS Potential therapeutic targetMET Therapeutic targetNF1/2 Tumor suppressor function, potential prognostic valueNOTCH1 Deregulation is a feature of tumorigenesisNRAS Potential therapeutic targetNTRK1/2/3 Potential gene fusion partner, therapeutic targetPDGFRA Potential therapeutic targetPIK3CA Potential response to TORC1 inhibitor rapamycin and its analogues: everolimus, temsirolimus, and

ridaforolimusPTEN Potential response to mTOR inhibitor everolimus, PI3K / AKT inhibitors under studySMAD4 Suspected gatekeeper geneSMO Implicated in the development of PCa and progression to more advanced and castration-resistant diseaseSRC Potential therapeutic targetSTK1 Tumor suppressor geneTP53 Patients with TP53 mutations may have better outcomes with bevacizumab, therapeutic targetTSC1/2 Suspected gatekeeper geneVHL Potential regulator of PDL1 expression

(profile components listing continued on back)

pathgroup.com | 855-854-6473

Fluorescence In Situ Hybridization (FISH)PTEN Prognostic and predictive in combination with ERGAR Provides therapeutic guidanceERG Prognostic and predictive in combination with PTEN

Cytogenomic Microarray (CMA)Whole genome copy number changes in >22,000 genes, 500 of which are implicated in cancer

12/2016